Previous trials with TCN-P, page-6

And really that's my main concern, AKTivate were only incorporated in 2014 and that's who we bought it off, so the shell pass around risk does exist. But like you said, "there's no doubt that TCN-P has anti-tumour activity", if VHL find the right combo then it could work out. At least DR Crombie seems legitimate with a reasonable track record so I'm kind of trusting in management a little here.

Certain drugs can do the rounds, for example I'm well aware that Tigris Pharmaceuticals had GGTI-2418 for a while there as well. But I don't really mind who had what in the past, just whether or not I can make a profit on the stock in the future. It's a high risk bio, I'm under no illusion.

Good luck to holders.